Sciact
  • EN
  • RU

Bicyclic monoterpenoid-based orthopoxvirus inhibitors: design, synthesis, and biological assessment of a novel amide series Full article

Journal RSC Medicinal Chemistry
, E-ISSN: 2632-8682
Output data Year: 2026, Volume: 17, Number: 5, DOI: 10.1039/d6md00217j
Authors Tishchenko Serafim A. 1,2 , Sokolova Anastasiya S. 1 , Samsonova Valeriya V. 1 , Pushkareva Julia G. 1,2 , Bormotov Nikolay I. 3 , Moskalev Ivan A. 4 , Solomina Daria.E. 1,2 , Rogachev Artem D. 1 , Fatyanova Alina V. 2 , Borisevich Sophia S. 4 , Yarovaya Olga I. 1 , Serova Olga A. 3 , Ovchinnikova Alena S. 3 , Sergeev Alexander A. 3 , Shishkina Larisa N. 3 , Sergeev Artemiy A. 3 , Agafonov Alexander P. 3 , Salakhutdinov Nariman F. 1
Affiliations
1 N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russian Federation
2 Novosibirsk State University, Novosibirsk 630090, Russian Federation
3 State Research Center of Virology and Biotechnology VECTOR (Rospotrebnadzor), Koltsovo, Novosibirsk Region 630559, Russian Federation
4 SRF “SKIF”, Koltsovo, Novosibirsk Region, 630559, Russian Federation

Abstract: This study reports the design, synthesis, and comprehensive biological evaluation of a new class of orthopoxvirus inhibitors utilizing natural bicyclic monoterpenoid scaffolds as strategic replacements for synthetic polycyclic cores. A focused library of amides based on camphor, apo-/isocamphane, and nopol-derived amines was synthesized and screened for activity against vaccinia (VACV), cowpox (CPXV), ectromelia (ECTV) and variola (VARV) viruses. Structure–activity relationship (SAR) analysis identified the importance of a para-substituted electron-withdrawing group on the benzamide moiety, with the apocamphanyl amine series yielding the most potent candidate, compound 13d. Compound 13d exhibited potent in vitro antiviral activity with IC50 values of 0.32 μM (VACV), 4.43 μM (CPXV), 3.28 μM (ECTV), and 1.6 μM (VARV) coupled with high selectivity indices (up to 1226). Further profiling revealed metabolic stability of 13d in mouse blood and favorable pharmacokinetics in mice following a single intragastric dose (100 mg kg−1), characterized by rapid absorption and a long elimination half-life (T1/2 ∼ 6.7 h), supportive of once-daily dosing. Computational studies involving pharmacophore analysis, molecular docking, and MD simulations elucidated the binding mode to the p37 phospholipase domain and rationalized the observed SAR, highlighting the critical role of hydrophobic interactions and stereochemistry. These findings validate the bicyclic monoterpenoid platform as a promising strategy for discovering potent, metabolically stable anti-orthopoxvirus agents and establish 13d as a compelling lead candidate for further preclinical development.
Cite: Tishchenko S.A. , Sokolova A.S. , Samsonova V.V. , Pushkareva J.G. , Bormotov N.I. , Moskalev I.A. , Solomina D.E. , Rogachev A.D. , Fatyanova A.V. , Borisevich S.S. , Yarovaya O.I. , Serova O.A. , Ovchinnikova A.S. , Sergeev A.A. , Shishkina L.N. , Sergeev A.A. , Agafonov A.P. , Salakhutdinov N.F.
Bicyclic monoterpenoid-based orthopoxvirus inhibitors: design, synthesis, and biological assessment of a novel amide series
RSC Medicinal Chemistry. 2026. V.17. N5. DOI: 10.1039/d6md00217j WOS Scopus OpenAlex
Dates:
Submitted: Mar 18, 2026
Accepted: Apr 5, 2026
Published online: Apr 9, 2026
Identifiers:
≡ Web of science: WOS:001746578300001
≡ Scopus: 2-s2.0-105036407049
≡ OpenAlex: W7152429720
Altmetrics: